PTGS2 and breast cancer: Some in vitro studies on breast cancer cells SUM149PT and SUM1315MO2 have shown interesting results in the context of nuclear PPAR-α receptor signaling, demonstrating that its activation by clofibrate agonist suppresses the inflammatory activity of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) and determines the decrease in the secretion of prostaglandin-E2 (PGE2) and leukotrienes-B4 (LB4), effectively inhibiting cell survival and cell cycle-related kinases [39].